Jump to content

John Katzenellenbogen

Add links
From Wikipedia, the free encyclopedia
(Redirected from Draft:John Katzenellenbogen)

John Albert Katzenellenbogen (born May 10, 1944) is an American Professor of Chemistry at the University of Illinois at Urbana-Champaign. He studies the development of novel agents for the treatment of hormone-responsive and non-responsive breast and prostate cancers and the design of estrogens and antiestrogens that have a favorable balance of beneficial versus detrimental effects.[1]

Early life

[edit]

John Katzenellenbogen was born May 10, 1944, in Poughkeepsie, New York. His parents taught at Vassar College, his father a professor of art history and his mother a pianist. In 1958, his family moved to Baltimore, Maryland, where his father became Head of the Department of Art History at Johns Hopkins University[2] and his mother joined the faculty at Peabody Conservatory[3] and Goucher College.[4] He began playing the cello at age 10. Katzenellenbogen attended Gilman School[5] and held various summer jobs: in 1960, he worked at the Research Institute for Advanced Studies in the photosynthesis lab of Dr. Bessel Kok,[6] and, in 1961, he was a General Electric Student Research Fellow at Union College in Schenectady, New York. As an undergraduate at Harvard, he majored in chemistry, going on to complete a PhD in chemistry in 1969 at Harvard under the direction of Dr. E. J. Corey.[7]

Career

[edit]

Katzenellenbogen began his academic career as an Assistant Professor of Chemistry at the University of Illinois at Urbana-Champaign[8] in 1969 and was promoted to Associate Professor in 1975 and to Full Professor in 1979. He was named the Roger Adams Professor and subsequently the chaired Swanlund Professor of Chemistry. He was one of the first academic chemists to work in the field of chemical biology. His major research efforts have focused on the study of steroid hormones and their biological receptors, the estrogen receptor in particular.

Katzenellenbogen's research is highly collaborative, and he works with other scientists locally, nationally, and internationally. He has published more than 550 articles[9] and has trained over 130 PhD's and Postdoctoral Associates. He is a member of the American Association for the Advancement of Science and a fellow of the American Academy of Arts and Sciences, on whose National Council he served for many years. He has received numerous awards from scientific societies, including the Arthur C. Cope Scholar Award,[10] the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances from the American Chemical Society,[11] the Endocrine Society's Fred Conrad Koch Lifetime Achievement Award,[12] which he shared with Dr. Benita Katzenellenbogen, and the Award for Outstanding Achievements in Chemistry in Cancer Research from the American Association for Cancer Research In 2018, Katzenellenbogen was inducted into the Medicinal Chemistry Hall of Fame of the American Chemical Society.

Research

[edit]

Katzenellenbogen developed the first affinity label for the estrogen receptor that was widely used to characterize its physical and biochemical properties,[13][14] and he elucidated the metabolic activation of antiestrogens and characterized their sites of action.[15] He also pioneered the development of positron emission tomography (PET) imaging agents for estrogen, androgen, and progesterone receptors.[16][17][18][19] The PET imaging agents he developed, FES,[20] FDHT,[21] and FFNP,[22] continue to be utilized to improve the prediction of patient response to endocrine therapy agents and to assist in the development of new cancer therapeutics. His more recent work is focused on developing novel antiestrogens effective against endocrine therapy-resistant forms of breast cancer[23][24] and dissecting the mechanisms and signaling pathways that underlie the selective actions of estrogens in different target tissues.[25][26][27][28]

References

[edit]
  1. ^ "John Katzenellenbogen". illinois.edu. Retrieved December 5, 2017.
  2. ^ "Dr. Adolf Katzenellenbogen, Johns Hopkins Professor, Dies". The New York Times. 1964-10-01. ISSN 0362-4331. Retrieved 2017-11-23.
  3. ^ "Scott Foglesong | SFCM". sfcm.edu. Retrieved 2017-11-23.
  4. ^ "Members of the Society". College Music Symposium. 10: 182. 1970. JSTOR 40376030.
  5. ^ "Fall 2015 Gilman Bulletin". issuu. Retrieved 2017-11-23.
  6. ^ "Notes: Elias James Corey". www.hcs.harvard.edu. Retrieved 2017-11-23.
  7. ^ "Group Members: Elias James Corey". www.hcs.harvard.edu. Archived from the original on 2021-04-22. Retrieved 2017-11-23.
  8. ^ "John A. Katzenellenbogen | Chemistry at Illinois". chemistry.illinois.edu. Retrieved 2017-11-22.
  9. ^ pubmeddev. "Katzenellenbogen JA - PubMed - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2017-11-22.
  10. ^ "Arthur C. Cope Scholar Awards - American Chemical Society". American Chemical Society. Retrieved 2017-11-22.
  11. ^ "E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances - American Chemical Society". American Chemical Society. Retrieved 2017-11-22.
  12. ^ "Katzenellenbogens Awarded Fred Conrad Koch Lifetime Achievement Award by the Endocrine Society | Chemistry at Illinois". chemistry.illinois.edu. Retrieved 2017-11-22.
  13. ^ Harlow, K. W.; Smith, D. N.; Katzenellenbogen, J. A.; Greene, G. L.; Katzenellenbogen, B. S. (1989-10-15). "Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor". The Journal of Biological Chemistry. 264 (29): 17476–17485. doi:10.1016/S0021-9258(18)71519-6. ISSN 0021-9258. PMID 2793867.
  14. ^ Robertson, D. W.; Wei, L. L.; Hayes, J. R.; Carlson, K. E.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. (October 1981). "Tamoxifen aziridines: effective inactivators of the estrogen receptor". Endocrinology. 109 (4): 1298–1300. doi:10.1210/endo-109-4-1298. ISSN 0013-7227. PMID 7285873.
  15. ^ Robertson, D. W.; Katzenellenbogen, J. A.; Long, D. J.; Rorke, E. A.; Katzenellenbogen, B. S. (January 1982). "Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen". Journal of Steroid Biochemistry. 16 (1): 1–13. doi:10.1016/0022-4731(82)90137-6. ISSN 0022-4731. PMID 7062732.
  16. ^ Katzenellenbogen, J. A.; Welch, M. J.; Dehdashti, F. (May 1997). "The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer". Anticancer Research. 17 (3B): 1573–1576. ISSN 0250-7005. PMID 9179196.
  17. ^ Mortimer, J. E.; Dehdashti, F.; Siegel, B. A.; Trinkaus, K.; Katzenellenbogen, J. A.; Welch, M. J. (2001-06-01). "Metabolic flare: indicator of hormone responsiveness in advanced breast cancer". Journal of Clinical Oncology. 19 (11): 2797–2803. doi:10.1200/JCO.2001.19.11.2797. ISSN 0732-183X. PMID 11387350.
  18. ^ Dehdashti, Farrokh; Picus, Joel; Michalski, Jeff M.; Dence, Carmen S.; Siegel, Barry A.; Katzenellenbogen, John A.; Welch, Michael J. (March 2005). "Positron tomographic assessment of androgen receptors in prostatic carcinoma". European Journal of Nuclear Medicine and Molecular Imaging. 32 (3): 344–350. doi:10.1007/s00259-005-1764-5. ISSN 1619-7070. PMID 15726353. S2CID 24329403.
  19. ^ Dehdashti, Farrokh; Mortimer, Joanne E.; Trinkaus, Kathryn; Naughton, Michael J.; Ellis, Matthew; Katzenellenbogen, John A.; Welch, Michael J.; Siegel, Barry A. (February 2009). "PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer". Breast Cancer Research and Treatment. 113 (3): 509–517. doi:10.1007/s10549-008-9953-0. ISSN 1573-7217. PMC 3883567. PMID 18327670.
  20. ^ Kiesewetter, D. O.; Kilbourn, M. R.; Landvatter, S. W.; Heiman, D. F.; Katzenellenbogen, J. A.; Welch, M. J. (November 1984). "Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats". Journal of Nuclear Medicine. 25 (11): 1212–1221. ISSN 0161-5505. PMID 6092569.
  21. ^ Liu, A.; Carlson, K. E.; Katzenellenbogen, J. A. (1992-05-29). "Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography". Journal of Medicinal Chemistry. 35 (11): 2113–2129. doi:10.1021/jm00089a024. ISSN 0022-2623. PMID 1597861.
  22. ^ Kochanny, M. J.; VanBrocklin, H. F.; Kym, P. R.; Carlson, K. E.; O'Neil, J. P.; Bonasera, T. A.; Welch, M. J.; Katzenellenbogen, J. A. (1993-04-30). "Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors". Journal of Medicinal Chemistry. 36 (9): 1120–1127. doi:10.1021/jm00061a002. ISSN 0022-2623. PMID 8487253.
  23. ^ Min, Jian; Guillen, Valeria Sanabria; Sharma, Abhishek; Zhao, Yuechao; Ziegler, Yvonne; Gong, Ping; Mayne, Christopher G.; Srinivasan, Sathish; Kim, Sung Hoon (2017-07-27). "Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells". Journal of Medicinal Chemistry. 60 (14): 6321–6336. doi:10.1021/acs.jmedchem.7b00585. ISSN 1520-4804. PMC 6039301. PMID 28657320.
  24. ^ Zhao, Yuechao; Laws, Mary J.; Guillen, Valeria Sanabria; Ziegler, Yvonne; Min, Jian; Sharma, Abhishek; Kim, Sung Hoon; Chu, David; Park, Ben Ho (2017-10-15). "Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors". Cancer Research. 77 (20): 5602–5613. doi:10.1158/0008-5472.CAN-17-1265. ISSN 1538-7445. PMC 5645250. PMID 28904064.
  25. ^ Madak-Erdogan, Zeynep; Kim, Sung Hoon; Gong, Ping; Zhao, Yiru C.; Zhang, Hui; Chambliss, Ken L.; Carlson, Kathryn E.; Mayne, Christopher G.; Shaul, Philip W. (2016-05-24). "Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues". Science Signaling. 9 (429): ra53. doi:10.1126/scisignal.aad8170. ISSN 1937-9145. PMC 4896643. PMID 27221711.
  26. ^ Zhao, Yuechao; Gong, Ping; Chen, Yiru; Nwachukwu, Jerome C.; Srinivasan, Sathish; Ko, CheMyong; Bagchi, Milan K.; Taylor, Robert N.; Korach, Kenneth S. (2015-01-21). "Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis". Science Translational Medicine. 7 (271): 271ra9. doi:10.1126/scitranslmed.3010626. ISSN 1946-6242. PMC 4790140. PMID 25609169.
  27. ^ Saijo, Kaoru; Collier, Jana G.; Li, Andrew C.; Katzenellenbogen, John A.; Glass, Christopher K. (2011-05-13). "An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation". Cell. 145 (4): 584–595. doi:10.1016/j.cell.2011.03.050. ISSN 1097-4172. PMC 3433492. PMID 21565615.
  28. ^ Moore, Spencer M.; Khalaj, Anna J.; Kumar, Shalini; Winchester, Zachary; Yoon, JaeHee; Yoo, Timothy; Martinez-Torres, Leonardo; Yasui, Norio; Katzenellenbogen, John A. (2014-12-16). "Multiple functional therapeutic effects of the estrogen receptor β agonist indazole-Cl in a mouse model of multiple sclerosis". Proceedings of the National Academy of Sciences of the United States of America. 111 (50): 18061–18066. Bibcode:2014PNAS..11118061M. doi:10.1073/pnas.1411294111. ISSN 1091-6490. PMC 4273334. PMID 25453074.
Retrieved from "https://en.wikipedia.org/w/index.php?title=John_Katzenellenbogen&oldid=1146358130"